sanofi q4 - Search News

Sanofi Q4 2024 sees strong growth in sales, EPS

Sanofi SA (SNY) Q4 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Investments ...

Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to enhance shareholder value.

The Motley Fool on MSN · 1d

Sanofi (SNY) Q4 2024 Earnings Call Transcript

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the usual forward-looking statements.

Business Insider · 2d

Press Release: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025

Sanofi: Q4 sales growth of 10.3%, 2024 business EPS guidance exceeded, and strong business EPS rebound expected in 2025Paris, January 30, 2025Q4:

GlobalData on MSN16h

Sanofi reports Q4 2024 increase in net income to $916m

Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ...

1don MSN

Sanofi CEO Paul Hudson on Q4 results: We've set ourselves up very well for 2025

Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, 2025 outlook, drug pipeline, ...

Sanofi Q4 Business Net Income Declines; Net Sales Up 10.3% At CER

Sanofi (SNYNF, SNY) reported fourth quarter net income from continuing operations of 880 million euros compared to a loss of 119 ...

Sanofi Expected to Report Lower Sales, Profit; Size of Buyback in Focus -- Earnings Preview

BUSINESS OPERATING PROFIT FORECAST: Business operating profit--one of the company's preferred metrics, which strips out exceptional items--is forecast at 2.08 billion euros, according to the Vara ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results